{"product_id":"regn-bcg-matrix","title":"(REGN) Regeneron Pharmaceuticals, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Regeneron Pharmaceuticals, Inc. BCG Matrix helps you see how the company’s products or business units fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDupixent $14B plus 7 indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDupixent is Regeneron Pharmaceuticals, Inc.’s biggest growth engine, with 2025 sales above $14B and 7 approved indications across type 2 inflammation. Its broad label keeps expanding, and the brand holds strong share in asthma, atopic dermatitis, COPD, and CRSwNP. That mix of fast growth, scale, and market leadership fits classic Star status in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDupixent COPD first U.S. biologic 2024\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDupixent’s 2024 U.S. COPD approval opened a huge new market, with COPD affecting about 16 million Americans and millions more undiagnosed. The launch pushed Dupixent beyond dermatology and asthma, supporting its 2024 global sales of about $13.6 billion. Even low share in COPD can add big revenue, so it stays a Star for Regeneron Pharmaceuticals, Inc.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDupixent atopic dermatitis category leader\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDupixent is Regeneron Pharmaceuticals, Inc.'s atopic dermatitis Star: the U.S. and global AD market is still large, and Dupixent reached $13.0 billion in 2024 sales, showing scale and demand. Broad adult and pediatric use, plus strong physician adoption, keeps share high and supports continued growth. That mix of high share and expansion is classic Star behavior.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDupixent asthma broad adult and pediatric use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDupixent is a Star because asthma is a long-duration market and the drug now serves broad adult and pediatric groups, including children as young as 6 months for certain asthma types. Regeneron said Dupixent remained a top growth engine in 2025, with global sales above the $14 billion scale set in 2024, and the brand keeps taking share from inhaled steroids and older biologics.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroad age reach supports repeat use\u003c\/li\u003e\n\u003cli\u003eChronic asthma means long treatment cycles\u003c\/li\u003e\n\u003cli\u003eSwitching from older therapy keeps growing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eARCALYST 2 orphan indications CAPS and recurrent pericarditis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eARCALYST has moved from a narrow CAPS orphan drug into a larger specialty franchise, and recurrent pericarditis has widened the addressable pool well beyond the ultra-rare CAPS base. The drug is FDA-approved for CAPS and recurrent pericarditis, and Regeneron has said the recurrent pericarditis launch expanded use into a much bigger market.\u003c\/p\u003e\n\u003cp\u003eThat is Star-like: the market is still growing, and ARCALYST has a strong niche position with clear clinical differentiation. CAPS remains tiny, but recurrent pericarditis adds far more patients, so the brand can keep scaling without needing a broad primary-care push.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCAPS is ultra-rare.\u003c\/li\u003e\n\u003cli\u003eRecurrent pericarditis expands reach.\u003c\/li\u003e\n\u003cli\u003eARCALYST has niche share strength.\u003c\/li\u003e\n\u003cli\u003eFit: Star in BCG matrix.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDupixent Powers Regeneron’s Growth With $14B+ Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDupixent is Regeneron Pharmaceuticals, Inc.’s clear Star: 2025 sales topped $14 billion, up from $13.6 billion in 2024, and the brand now spans 7 approved indications. Its growth in asthma, atopic dermatitis, COPD, and CRSwNP shows high share plus fast expansion.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2025 Sales\u003c\/th\u003e\n\u003cth\u003eBCG fit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eDupixent\u003c\/td\u003e\n\u003ctd\u003eAbove $14B\u003c\/td\u003e\n\u003ctd\u003eStar\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eRegeneron’s BCG Matrix maps its portfolio to spot Stars, Cash Cows, Question Marks, and Dogs for smart invest\/hold\/divest calls.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page Regeneron BCG Matrix to quickly spot pain-point relievers and growth bets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eRegeneron Pharmaceuticals, Inc. Reference Sources provide a credible audit trail that strengthens trust and supports faster, better decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEylea 2 mg wet AMD multibillion revenue base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEylea 2 mg still anchors Regeneron Pharmaceuticals, Inc.'s wet AMD franchise, which remains a mature but cash-rich legacy market. Even as newer anti-VEGF options and biosimilars pressure growth, the 2 mg brand still drives billions in annual sales and supports high operating cash flow. That steady, lower-growth, high-margin profile is classic Cash Cow behavior.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEylea 2 mg diabetic macular edema\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDME is a large, established retinal market, and Eylea 2 mg still holds a strong share in a mature segment. Regeneron Pharmaceuticals, Inc. said Eylea franchise sales were still in the multi-billion-dollar range in its latest filings, but growth has slowed as the market matures and newer dosing options expand. That fits Cash Cow economics: steady cash flow, lower launch support, and limited incremental spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEylea 2 mg retinal vein occlusion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEylea 2 mg for retinal vein occlusion sits in a mature market with stable prescribing and strong brand recognition. Regeneron generated $5.45 billion in Eylea U.S. net sales in 2024, showing the franchise still throws off major cash even as growth slows. That makes RVO a classic Cash Cow: dependable income, not rapid expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEylea ex-U.S. Bayer collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOutside the U.S., Eylea is a mature, low-promo franchise run through Bayer’s long-set collaboration with Regeneron Pharmaceuticals, Inc., with Regeneron typically sharing 50% of profits and losses. Strong brand awareness and Bayer’s established sales force keep demand steady, so this line keeps turning cash with limited fresh spending.\u003c\/p\u003e\n\u003cp\u003eEylea’s ex-U.S. role fits Cash Cow status because the market is already built, physician adoption is entrenched, and the product has been commercialized for years since its 2012 EU launch. Even as Regeneron pushes newer drugs, this collaboration still provides recurring economics and stable contribution.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e50% profit-share economics\u003c\/li\u003e\n\u003cli\u003eEstablished ex-U.S. sales channel\u003c\/li\u003e\n\u003cli\u003eLow promotion needs\u003c\/li\u003e\n\u003cli\u003eMature, high-recognition brand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEylea legacy franchise 2024 cash generation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEylea remains a Cash Cow for Regeneron Pharmaceuticals, Inc.: the legacy franchise still throws off strong cash even as biosimilar pressure slows growth. In 2024, the business stayed highly profitable and helped fund a large share of Regeneron Pharmaceuticals, Inc. R\u0026amp;D spend, which was about $5.9 billion. Mature share, strong margins, and repeat demand keep it a key funding source.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEylea still funds Regeneron Pharmaceuticals, Inc. R\u0026amp;D.\u003c\/li\u003e\n\u003cli\u003eGrowth slowed under biosimilar pressure.\u003c\/li\u003e\n\u003cli\u003eHigh margins fit a Cash Cow profile.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEylea 2 mg Powers Regeneron’s Cash Flow Engine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEylea 2 mg is Regeneron Pharmaceuticals, Inc.'s main Cash Cow: a mature retinal franchise with strong repeat demand, high margins, and lower growth needs. In 2024, Regeneron Pharmaceuticals, Inc. reported $5.45 billion in U.S. Eylea net sales, while R\u0026amp;D was about $5.9 billion, showing how the franchise helps fund innovation.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash Cow\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eEylea 2 mg\u003c\/td\u003e\n\u003ctd\u003e$5.45B U.S. net sales; mature market; high cash flow\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eRegeneron Pharmaceuticals, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eYou’re previewing the exact Regeneron Pharmaceuticals, Inc. BCG Matrix document you’ll receive after purchase. The full file includes the same analysis, formatting, and structure shown here. No demo content or placeholders—just the finished report, ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eREGEN-COV 0 active commercial use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eREGEN-COV has no active commercial use for Regeneron Pharmaceuticals, Inc.; FDA authorization was effectively ended as Omicron-era variants made it ineffective. With no current COVID demand and no clear turnaround path, it generates no meaningful sales and fits the Dogs quadrant. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZALTRAP metastatic colorectal cancer low uptake\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZALTRAP (ziv-aflibercept) remains a niche mCRC drug in a crowded oncology field dominated by bevacizumab and newer regimens. Regeneron does not disclose material ZALTRAP revenue in recent filings, which points to very low uptake and little growth. With weak share and limited strategic value, ZALTRAP fits the Dog bucket.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePraluent PCSK9 share below Repatha\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePraluent sits in a mature PCSK9 market that is led by Repatha, which posted about $2.0 billion in 2024 sales. Praluent has stayed well behind for years, with limited growth and much smaller economic value. That weak share, in a slow-growing category, fits Dog territory in the BCG matrix. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eKevzara rheumatoid arthritis mature competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKevzara sits in a crowded, mature RA market with entrenched TNF and JAK rivals, so it has not become a dominant brand. Regeneron Pharmaceuticals, Inc. reported $14.2 billion in 2024 revenue, while Kevzara remained a small contributor versus newer assets like Dupixent, which keeps it in the Dog box.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRA market is mature and crowded\u003c\/li\u003e\n\u003cli\u003eKevzara lacks category leadership\u003c\/li\u003e\n\u003cli\u003eSales are small versus Regeneron core assets\u003c\/li\u003e\n\u003cli\u003eLow growth, low share = Dog\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInmazeb Zaire ebolavirus outbreak driven demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInmazeb is tied to rare, outbreak-based Zaire ebolavirus demand, so sales are episodic rather than recurring. Regeneron Pharmaceuticals, Inc. gets no broad scale from it; the market only opens during Ebola flareups, which are infrequent and often localized. That makes Inmazeb a clear Dog in the BCG Matrix: low growth, limited volume, and weak long-term scale potential.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRare, outbreak-driven demand\u003c\/li\u003e\n\u003cli\u003eNo steady commercial run-rate\u003c\/li\u003e\n\u003cli\u003eLimited scale and revenue ceiling\u003c\/li\u003e\n\u003cli\u003eBCG fit: Dog\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegeneron’s “Dog” products stay small, weak-growth, and non-core\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRegeneron Pharmaceuticals, Inc. Dogs are legacy or niche products with weak growth and low share. REGEN-COV, ZALTRAP, Praluent, Kevzara, and Inmazeb add little to 2025\/2026 sales and face shrinking or episodic demand.\u003c\/p\u003e\n\u003cp\u003eWith Regeneron Pharmaceuticals, Inc. 2025 revenue still driven by Dupixent and EYLEA, these brands remain small and non-core. Low growth plus low market share keeps them in the Dog quadrant.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2025\/2026 signal\u003c\/th\u003e\n\u003cth\u003eBCG\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eREGEN-COV\u003c\/td\u003e\n\u003ctd\u003eNo active commercial use\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZALTRAP\u003c\/td\u003e\n\u003ctd\u003eMinimal disclosed sales\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePraluent\u003c\/td\u003e\n\u003ctd\u003eWeak PCSK9 share\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKevzara\u003c\/td\u003e\n\u003ctd\u003eSmall in crowded RA\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInmazeb\u003c\/td\u003e\n\u003ctd\u003eOutbreak-driven demand\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEylea HD 8 mg launched 2023\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEylea HD 8 mg, launched in 2023, targets the same wet AMD, DME, and RVO market as Eylea but with dosing up to every 16 weeks after the loading phase. Uptake is rising, but Regeneron Pharmaceuticals, Inc. now faces sharper competition and aflibercept biosimilars, so share is still being built. That makes it a Question Mark in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLibtayo PD-1 oncology franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLibtayo sits in a huge PD-1 market led by Merck’s Keytruda and BMS’s Opdivo; Keytruda alone posted about $29.5B in 2024 sales. Regeneron Pharmaceuticals, Inc. has approved uses in CSCC, NSCLC, and cervical cancer, but Libtayo’s scale is still far smaller, with 2024 net product sales near $1.3B. Growth is possible, yet the franchise is not secure against the category leaders, so it fits a Question Mark in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLinvoseltamab BCMAxCD3 late-stage myeloma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMultiple myeloma is a growing hematology market, with roughly 36,000 new U.S. cases a year and a global market already in the tens of billions. Linvoseltamab is still a developing BCMAxCD3 asset, so its market share is unproven today. If clinical and regulatory momentum holds, it could scale fast; for now, it fits Regeneron Pharmaceuticals, Inc. as a Question Mark.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eItepekimab IL-33 COPD and asthma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eItepekimab, Regeneron Pharmaceuticals, Inc.’s IL-33 antibody, sits in a huge but still open market: COPD affects about 390 million people and asthma about 262 million worldwide. It has no commercial share yet because it is still in development, so the near-term revenue is zero. That mix of big upside and high trial risk fits a Question Mark.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eLarge need, no sales yet.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eHigh upside, but approval is uncertain.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFianlimab LAG-3 immuno-oncology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFianlimab sits in a Question Mark spot in Regeneron Pharmaceuticals, Inc.'s BCG Matrix: LAG-3 is a real growth area, but Regeneron has 0% commercial share today because fianlimab is still not approved. The upside is meaningful, since the LAG-3 class already reached market with 1 approved combo therapy, but fianlimab still needs strong late-stage data and regulatory wins.\u003c\/p\u003e\n\u003cp\u003eIt can become a star asset, but for now it is a high-risk, high-reward bet.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket share today: 0%\u003c\/li\u003e\n\u003cli\u003eNot yet a commercial product\u003c\/li\u003e\n\u003cli\u003eLAG-3 has 1 approved therapy classwide\u003c\/li\u003e\n\u003cli\u003eNeeds data, approval, and launch\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegeneron’s High-Upside, Low-Share Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEylea HD, Libtayo, and linvoseltamab are Regeneron Pharmaceuticals, Inc. Question Marks: each has a big market, but share is still being built. Libtayo reached about $1.3B in 2024 sales, while Keytruda was about $29.5B, showing the gap. Itepekimab and fianlimab still have no commercial sales, so upside is high but risk is too.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003cth\u003e2024\/25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLibtayo\u003c\/td\u003e\n\u003ctd\u003eLow share\u003c\/td\u003e\n\u003ctd\u003e$1.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKeytruda\u003c\/td\u003e\n\u003ctd\u003eMarket leader\u003c\/td\u003e\n\u003ctd\u003e$29.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFianlimab\u003c\/td\u003e\n\u003ctd\u003eNo sales\u003c\/td\u003e\n\u003ctd\u003e0%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57191850967305,"sku":"regn-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/regn-bcg-matrix.webp?v=1783678600","url":"https:\/\/dcfanalyst.com\/products\/regn-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}